ArticleActa clinica Croatica2025
IS THERE A PROGNOSTIC ROLE OF FOCAL ADHESION KINASE AND CD8 IN SQUAMOUS CELL HEAD AND NECK CANCER TREATED WITH RADIOTHERAPY?
Article in Acta clinica Croatica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of relapses in advanced squamous cell head and neck cancer (SCHNC) is significant, and so is treatment morbidity. There is persistent need for reliable biomarkers in order to better personalize treatment. The purpose of the present study was to evaluate prognostic significance of focal adhesion kinase (FAK) and CD8 expression in human papillomavirus (HPV) negative SCHNC treated with radiotherapy. FAK and CD8 expression was evaluated by immunohistochemical staining. A total of 62 tissue samples were assessed. High expression of FAK was determined in 37.1% and high expression of CD8 in 25.8% of study patients. Patients with high expression of FAK had significantly more relapses than patients with low FAK expression (p=0.04). FAK and CD8 expression had no significant impact on overall survival (OS) (p=0.44 and p=0.48, respectively) and relapse free survival (RFS) (p=0.21 and p=0.31, respectively). However, patients with high expression of FAK and low expression of CD8 had the worst 5-year OS (38.7%) and 5-year RFS (44.3%). Patients with low expression of FAK had significantly less relapses. The prognostic role of FAK and CD8 expression in SCHNC patients treated with radiotherapy was not proven.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.